NASDAQ:UFPT

UFP Technologies Competitors

$49.87
-0.04 (-0.08 %)
(As of 04/20/2021 04:30 PM ET)
Add
Compare
Today's Range
$49.21
Now: $49.87
$50.51
50-Day Range
$47.64
MA: $50.57
$53.70
52-Week Range
$36.69
Now: $49.87
$55.51
Volume23,407 shs
Average Volume30,268 shs
Market Capitalization$375.02 million
P/E Ratio24.94
Dividend YieldN/A
Beta0.92

Competitors

UFP Technologies (NASDAQ:UFPT) Vs. MDXG, ATRI, SIBN, TCMD, LMAT, and KIDS

Should you be buying UFPT stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to UFP Technologies, including MiMedx Group (MDXG), Atrion (ATRI), SI-BONE (SIBN), Tactile Systems Technology (TCMD), LeMaitre Vascular (LMAT), and OrthoPediatrics (KIDS).

UFP Technologies (NASDAQ:UFPT) and MiMedx Group (NASDAQ:MDXG) are both small-cap industrial products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

76.1% of UFP Technologies shares are held by institutional investors. Comparatively, 4.0% of MiMedx Group shares are held by institutional investors. 11.0% of UFP Technologies shares are held by company insiders. Comparatively, 19.8% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares UFP Technologies and MiMedx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UFP Technologies8.12%8.94%7.67%
MiMedx Group-37.28%-404.08%-58.81%

Risk and Volatility

UFP Technologies has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Valuation & Earnings

This table compares UFP Technologies and MiMedx Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UFP Technologies$198.38 million1.89$19.75 million$2.6318.96
MiMedx Group$299.26 million4.03$-25,580,000.00N/AN/A

UFP Technologies has higher earnings, but lower revenue than MiMedx Group.

Analyst Ratings

This is a summary of recent ratings and target prices for UFP Technologies and MiMedx Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UFP Technologies00203.00
MiMedx Group00103.00

MiMedx Group has a consensus target price of $20.00, indicating a potential upside of 84.50%. Given MiMedx Group's higher possible upside, analysts clearly believe MiMedx Group is more favorable than UFP Technologies.

Summary

UFP Technologies beats MiMedx Group on 7 of the 12 factors compared between the two stocks.

UFP Technologies (NASDAQ:UFPT) and Atrion (NASDAQ:ATRI) are both small-cap industrial products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings for UFP Technologies and Atrion, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UFP Technologies00203.00
Atrion0000N/A

Profitability

This table compares UFP Technologies and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UFP Technologies8.12%8.94%7.67%
Atrion21.90%13.90%12.55%

Institutional and Insider Ownership

76.1% of UFP Technologies shares are held by institutional investors. Comparatively, 63.2% of Atrion shares are held by institutional investors. 11.0% of UFP Technologies shares are held by insiders. Comparatively, 22.4% of Atrion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

UFP Technologies has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

Valuation and Earnings

This table compares UFP Technologies and Atrion's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UFP Technologies$198.38 million1.89$19.75 million$2.6318.96
Atrion$155.07 million7.68$36.76 millionN/AN/A

Atrion has lower revenue, but higher earnings than UFP Technologies.

Summary

Atrion beats UFP Technologies on 7 of the 11 factors compared between the two stocks.

UFP Technologies (NASDAQ:UFPT) and SI-BONE (NASDAQ:SIBN) are both small-cap industrial products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Risk & Volatility

UFP Technologies has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares UFP Technologies and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UFP Technologies8.12%8.94%7.67%
SI-BONE-61.67%-45.03%-29.29%

Analyst Ratings

This is a summary of recent ratings and recommmendations for UFP Technologies and SI-BONE, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UFP Technologies00203.00
SI-BONE00503.00

SI-BONE has a consensus target price of $33.20, indicating a potential downside of 0.75%. Given SI-BONE's higher probable upside, analysts clearly believe SI-BONE is more favorable than UFP Technologies.

Valuation & Earnings

This table compares UFP Technologies and SI-BONE's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UFP Technologies$198.38 million1.89$19.75 million$2.6318.96
SI-BONE$67.30 million16.27$-38,400,000.00($1.55)-21.59

UFP Technologies has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.1% of UFP Technologies shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 11.0% of UFP Technologies shares are owned by company insiders. Comparatively, 15.5% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

UFP Technologies beats SI-BONE on 8 of the 13 factors compared between the two stocks.

UFP Technologies (NASDAQ:UFPT) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap industrial products companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility and Risk

UFP Technologies has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.

Valuation and Earnings

This table compares UFP Technologies and Tactile Systems Technology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UFP Technologies$198.38 million1.89$19.75 million$2.6318.96
Tactile Systems Technology$189.49 million5.59$10.97 million$0.5696.27

UFP Technologies has higher revenue and earnings than Tactile Systems Technology. UFP Technologies is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares UFP Technologies and Tactile Systems Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UFP Technologies8.12%8.94%7.67%
Tactile Systems Technology-4.57%1.37%0.99%

Insider and Institutional Ownership

76.1% of UFP Technologies shares are held by institutional investors. 11.0% of UFP Technologies shares are held by company insiders. Comparatively, 5.3% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for UFP Technologies and Tactile Systems Technology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UFP Technologies00203.00
Tactile Systems Technology01202.67

Tactile Systems Technology has a consensus target price of $59.00, indicating a potential upside of 9.44%. Given Tactile Systems Technology's higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than UFP Technologies.

Summary

UFP Technologies beats Tactile Systems Technology on 10 of the 13 factors compared between the two stocks.

LeMaitre Vascular (NASDAQ:LMAT) and UFP Technologies (NASDAQ:UFPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Institutional and Insider Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 76.1% of UFP Technologies shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 11.0% of UFP Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for LeMaitre Vascular and UFP Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LeMaitre Vascular04202.33
UFP Technologies00203.00

LeMaitre Vascular currently has a consensus target price of $36.60, indicating a potential downside of 26.89%. Given LeMaitre Vascular's higher probable upside, research analysts plainly believe LeMaitre Vascular is more favorable than UFP Technologies.

Profitability

This table compares LeMaitre Vascular and UFP Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LeMaitre Vascular15.41%12.32%8.45%
UFP Technologies8.12%8.94%7.67%

Earnings & Valuation

This table compares LeMaitre Vascular and UFP Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LeMaitre Vascular$117.23 million8.76$17.93 million$0.8856.85
UFP Technologies$198.38 million1.89$19.75 million$2.6318.96

UFP Technologies has higher revenue and earnings than LeMaitre Vascular. UFP Technologies is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, UFP Technologies has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Summary

LeMaitre Vascular beats UFP Technologies on 9 of the 13 factors compared between the two stocks.

OrthoPediatrics (NASDAQ:KIDS) and UFP Technologies (NASDAQ:UFPT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Valuation & Earnings

This table compares OrthoPediatrics and UFP Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$72.55 million14.11$-13,730,000.00($0.87)-59.85
UFP Technologies$198.38 million1.89$19.75 million$2.6318.96

UFP Technologies has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than UFP Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

OrthoPediatrics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, UFP Technologies has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Institutional and Insider Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 76.1% of UFP Technologies shares are owned by institutional investors. 33.6% of OrthoPediatrics shares are owned by company insiders. Comparatively, 11.0% of UFP Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares OrthoPediatrics and UFP Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrthoPediatrics-34.26%-11.57%-8.79%
UFP Technologies8.12%8.94%7.67%

Analyst Ratings

This is a breakdown of current ratings for OrthoPediatrics and UFP Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrthoPediatrics00303.00
UFP Technologies00203.00

OrthoPediatrics currently has a consensus price target of $58.1429, suggesting a potential upside of 11.90%. Given OrthoPediatrics' higher probable upside, equities analysts clearly believe OrthoPediatrics is more favorable than UFP Technologies.

Summary

UFP Technologies beats OrthoPediatrics on 9 of the 13 factors compared between the two stocks.


UFP Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MiMedx Group logo
MDXG
MiMedx Group
1.7$10.83-4.7%$1.26 billion$299.26 million-11.52News Coverage
Atrion logo
ATRI
Atrion
1.1$651.58-0.2%$1.19 billion$155.07 million36.71
SI-BONE logo
SIBN
SI-BONE
1.2$33.46-3.7%$1.14 billion$67.30 million-20.91Analyst Report
News Coverage
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$53.91-0.1%$1.06 billion$189.49 million-119.80
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$50.03-0.9%$1.04 billion$117.23 million53.80
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$52.07-0.3%$1.03 billion$72.55 million-36.16Analyst Report
News Coverage
Cerus logo
CERS
Cerus
1.7$5.84-1.4%$995.86 million$74.65 million-14.97News Coverage
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.54-1.7%$912.62 million$264.16 million-5.27Decrease in Short Interest
CryoLife logo
CRY
CryoLife
2.0$22.54-0.2%$883.33 million$276.22 million-59.31News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.89-0.3%$854.04 million$459.95 million36.58
Surmodics logo
SRDX
Surmodics
1.3$57.51-0.3%$789.04 million$94.86 million718.88
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.42-0.8%$683.49 million$154.60 million-40.96
Intersect ENT logo
XENT
Intersect ENT
1.7$19.50-0.9%$649.76 million$109.14 million-10.21Analyst Upgrade
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.84-1.6%$645.74 million$123.86 million64.01
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.60-1.6%$572.63 million$114.51 million-86.38
SeaSpine logo
SPNE
SeaSpine
1.5$19.82-0.7%$557.70 million$159.08 million-11.87
Vapotherm logo
VAPO
Vapotherm
1.5$21.30-0.9%$554.85 million$48.10 million-10.14
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$19.93-2.3%$531.65 millionN/A-8.78
Accuray logo
ARAY
Accuray
2.3$4.93-4.7%$479.35 million$382.93 million35.21Upcoming Earnings
News Coverage
iCAD logo
ICAD
iCAD
1.7$16.99-3.6%$438.56 million$31.34 million-17.88
AVITA Medical logo
RCEL
AVITA Medical
1.5$19.87-1.3%$435.18 million$14.26 million-9.60
Profound Medical logo
PROF
Profound Medical
1.6$18.74-7.0%$407.02 million$4.17 million-16.02
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.75-2.3%$387.21 million$24.95 million-26.52News Coverage
PAVmed logo
PAVM
PAVmed
1.4$4.26-5.6%$371.07 millionN/A-5.61
Acutus Medical logo
AFIB
Acutus Medical
1.3$12.91-0.2%$363.55 million$2.84 million0.00
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$17.48-1.4%$356.20 million$11.22 million-39.73
Soliton logo
SOLY
Soliton
1.2$14.67-7.4%$334.11 millionN/A-19.56Analyst Downgrade
Analyst Revision
News Coverage
Apyx Medical logo
APYX
Apyx Medical
1.0$9.88-2.4%$330.83 million$28.15 million-21.02
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.04-0.1%$317.82 million$46.90 million27.46Upcoming Earnings
News Coverage
IRadimed logo
IRMD
IRadimed
1.5$25.85-1.4%$313.68 million$38.52 million80.78Gap Down
Neuronetics logo
STIM
Neuronetics
1.5$10.76-3.2%$285.65 million$62.66 million-6.40
DarioHealth logo
DRIO
DarioHealth
1.3$16.52-4.3%$265.26 million$7.56 million-2.07
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$8.19-7.4%$234.78 million$220,000.0010.11
TELA Bio logo
TELA
TELA Bio
2.1$13.56-0.1%$196.10 million$15.45 million-4.66
Titan Medical logo
TMDI
Titan Medical
1.2$1.49-7.4%$175.24 millionN/A149.00Gap Up
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.18-0.0%$175.22 million$8.34 million-1.71
PolyPid logo
PYPD
PolyPid
1.4$9.59-1.7%$166.20 millionN/A0.00News Coverage
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.72-8.4%$161.10 million$50.71 million-4.61Decrease in Short Interest
Gap Up
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$10.15-8.0%$142.07 millionN/A0.00Gap Up
Brainsway logo
BWAY
Brainsway
1.3$8.30-7.5%$131.66 million$23.10 million-25.94Analyst Report
Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.02-5.6%$126.76 million$23.16 million-302.00
Nemaura Medical logo
NMRD
Nemaura Medical
0.2$4.91-8.1%$121.76 millionN/A-24.55Increase in Short Interest
Gap Up
Liquidia logo
LQDA
Liquidia
1.5$2.83-4.2%$117.44 million$8.07 million-1.33Analyst Downgrade
Beyond Air logo
XAIR
Beyond Air
1.7$5.21-1.9%$108.79 million$1.39 million-3.32
Avinger logo
AVGR
Avinger
1.4$0.97-13.4%$104.83 million$9.13 million-0.74Analyst Downgrade
Decrease in Short Interest
Gap Up
Venus Concept logo
VERO
Venus Concept
1.9$1.77-6.2%$101.47 million$110.41 million-0.53
Pro-Dex logo
PDEX
Pro-Dex
0.7$25.98-0.9%$101.20 million$34.83 million26.97Increase in Short Interest
LENSAR logo
LNSR
LENSAR
1.7$7.00-0.1%$76.42 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Delcath Systems logo
DCTH
Delcath Systems
1.9$11.96-1.8%$76.08 million$1.58 million-0.01
Nephros logo
NEPH
Nephros
2.0$7.30-2.9%$74.74 million$10.33 million-15.87News Coverage
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.